Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer

European Journal of Surgical Oncology

Volumn 29, Issue 8, 2003, Pages 654-657

  Tomita, M ^a   Matsuzaki, Y ^a   Edagawa, M ^a   Shimizu, T ^a   Hara, M ^a   Onitsuka, T ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

bcl 2; Lung cancer; pN2

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 0141885988     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(03)00138-0     Document Type: Article

References (29)

1. Paulson DL, Reisch JS. Long-term survival after resection for broncgogenic carcinoma. Ann Surg 1976; 184: 324-32.
2. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin N Am 1987; 67: 1037-48.
3. Watanabe Y, Hayashi Y, Shimizu J, Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest 1991; 100: 422-8.
4. Riquet M, Manac'h D, Saab M, Le Pimpec-Barthes F, Dujon A, Debesse B. Factors determining survival in resected N2 lung cancer. Eur J Cardiothorac Surg 1995; 9: 300-4.
5. Regnard JF, Magdeleinat P, Azoulay D et al. Results of resection for bronchogenic carcinoma with mediastinal lymph node metastases in selected patients. Eur J Cardiothorac Surg 1991; 5: 583-6.
6. van Klaveren RJ, Festen J, Otten HJ, Cox AL, de Graaf R, Lacquet LK. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg 1993; 56: 300-4.
7. Maggi G, Casadio C, Cianci R et al. Results of surgical resection of stage IIIa (N2) non small cell lung cancer, according to the site of the mediastinal metastases. Int Surg 1993; 78: 213-7.
8. Goldstraw P, Mannam GC, Kaplan DK, Michail P. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 1994; 107: 19-27.
9. Vansteenkiste JF, De Leyn PR, Deneffe GJ et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 1997; 63: 1441-50.
10. Yano T, Fukuyama Y, Yokoyama H et al. Long-term survivors with pN2 non-small cell lung cancer after a complete resection with a systematic mediastinal node dissection. Eur J Cardiothorac Surg 1998; 14: 152-5.
11. Sagawa M, Sakurada A, Fujimura S et al. Five-year survivors with resected pN2 nonsmall cell lung carcinoma. Cancer 1999; 85: 864-8.
12. Bunn PA Jr., Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest 2000; 117: 1635-85.
13. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-31.
14. Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, Kawakami Y. Prognostic significance of p53 and ras p21 expression in non-small cell lung cancer. Cancer 1995; 76: 2457-63.
15. Lee JS, Yoon A, Kalapurakal SK et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893-903.
16. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66: 735-8.
17. Brambilla E, Gazzeri S, Moro D et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993; 143: 199-210.
18. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997; 80: 1034-45.
19. Pezzella F, Turley H, Kuzu I et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-4.
20. Fontanini G, Vignati S, Bigini D et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71: 1003-7.
21. Koukourakis MI, Giatromanolaki A, O'Byrne KJ et al. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer 1997; 74: 565-70.
22. Silvestrini R, Costa A, Lequaglie C et al. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch 1998; 432: 441-4.
23. Cox G, Louise Jones J, Andi A, Abrams KR, O'Byrne KJ. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer 2001; 34: 417-26.
24. Gaffney EF, O'Neil AJ, Staunton MJ. Bcl-2 and prognosis in non-small-cell lung carcinoma. N Engl J Med 1994; 330: 1757-8.
25. Anton RC, Brown RW, Younes M, Gondo MM, Stephenson MA, Cagle PT. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: analysis of 427 cases. Hum Pathol 1997; 28: 1079-82.
26. Fleming MV, Guinee DG Jr., Chu WS et al. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol 1998; 29: 60-4.
27. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases. Ann Surg 2000; 232: 112-8.
28. Faber LP, Kittle CF, Warren WH et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989; 47: 669-77.
29. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-8.